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Abstract
Background: Japanese encephalitis (JE) vaccination is the most effective measure for preventing JE disease. The
live attenuated JE vaccine, which has shown good efficacy and safety, has been widely used in China.
Case presentations: We report four laboratory-confirmed JE cases detected in JE-endemic areas during the JE
virus (JEV) transmission season, who all received a first dose of live attenuated JE vaccine within 2 weeks prior to
the onset of illness. All cases presented with acute encephalitis and rapidly reduced consciousness. All
cerebrospinal fluid (CSF) samples from the patients were positive for JEV-specific immunoglobulin M (IgM)
antibodies, but viral isolation and polymerase chain reaction (PCR) detection of JEV were both negative.
Conclusions: It is difficult to identify a causal link between the disease and the vaccination, as the source of
positive CSF JEV IgM antibodies might be natural JEV infection or possibly due to a traumatic lumbar puncture.
Our observations highlight the need for public health officers and doctors to consider reasonable vaccination
policies during the JE season. In addition, continued surveillance as well as thorough investigation of any events
that occur after JE vaccination is necessary.
Background
Japanese encephalitis (JE), a major cause of acute viral
encephalitis, affects approximately 30,000-50,000 of the
population and causes up to 15,000 deaths annually in
Asia. The disease occurs throughout most of Asia and
parts of the western Pacific. In parts of Asia, it is princi-
pally a disease of children living in rural areas [1]. In the
absence of specific antiviral treatment, the World Health
Organization (WHO) and most affected countries have
placed a high public health priority on vaccination.
After a nationwide vaccination program was initiated
in the late 1970s in China, the incidence of JE dramati-
cally decreased from 20.92/100,000 people in 1971 to
0.23/100,000 people in 2008 [1]. In China, inactivated
(P3 strain) and live attenuated (SA14-14-2 strain) JE
vaccines were developed. The inactivated vaccine was
introduced in the mid-1970s and played a major role in
reducing JE incidence in the 1980s and 1990s [1]. The
live attenuated vaccine, developed in 1988, provided
excellent effectiveness (88%-96%) and good safety [2-7]
and replaced the inactivated vaccine in many provinces.
At present, more than 110 million doses of JE vaccines
are produced annually in China, in excess of domestic
demand, and nearly 120 million children have been
reached through vaccine campaigns and routine immu-
nization [1]. Recently, one report summarized a small
number of adverse events temporally associated with JE
vaccination in China from 1994 to 2004. The majority
of these cases were detected in county or lower level
hospitals and were characterized by hypersensitivity-type
reactions that occurred shortly after vaccination [8].
However, this report did not clearly discriminate the
type of vaccine administered. Here, we describe four
laboratory-confirmed JE infections temporally associated
with live attenuated JE vaccine administration.
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veillance in two JE-endemic rural districts in Yunnan,
China, from May to December 2009. The two districts
showed a high JE annual average incidence of 2.47-4.4/
100,000 people from 2000 to 2007, and JE cases occur
during every month of the year, but peak from July to
October [9]. JE was confirmed by one or more of the
following: a JE virus (JEV)-specific immunoglobulin M
(IgM) antibody-capture enzyme-linked immunosorbent
assay (MAC-ELISA) (Shanghai B & C Enterprise Devel-
o p m e n tC o .L t d ,S h a n g h a i ,C h i n a )[ 1 0 ] ,r e v e r s et r a n -
scription semi-nested polymerase chain reaction (PCR),
or virus isolation from serum or cerebrospinal fluid
(CSF) obtained from patients with viral encephalitis who
were admitted to local county hospitals. The JEV MAC-
ELISA remains the principal method for laboratory con-
firmation of JE in China [10]. JEV ELISA for the patients
was repeated both by the local hospital and by Beijing
Institute of Microbiology and Epidemiology. Of the 84
patients investigated, 36 (43%) were positive for JEV
infection. Three JEV isolates were obtained (GenBank
no. GU371870; GU371871; GU371872) and all were
identified as genotype I. The viral encephalitis surveil-
lance was performed after consultation with the patients
or their guardians and after the receipt of written con-
sent. The study-related information was used anon-
ymously. The Institutional Review Board of the Beijing
Institute of Microbiology and Epidemiology approved
the research involving human materials.
Case presentations
Of 36 laboratory-confirmed JE cases, four cases had
been vaccinated with a first dose (0.5 ml) of live attenu-
ated JE vaccine (Chengdu Institute of Biological Pro-
ducts, China) within 2 weeks prior to the onset of
illness. Characteristics of the cases are summarized in
Table 1. Case 1, a nine-month-old girl, was admitted to
local pediatric hospital A on 4 September with rapidly
progressive encephalopathy. She was febrile on 31
August. At the admission, she had a temperature of
38.3°C, and was drowsy. Neck stiffness, positive Kernig’s
sign, uncontrolled shaking of the body and hypertonia
were also present. No rash was noticed. Eleven days
prior to the onset of fever, she received the live attenu-
ated JE vaccine. Case 2 was a previously healthy four-
year-old boy. He was admitted to local hospital B on 30
June with a severe headache. At hospital admission, he
had a temperature of 39°C, vomiting, neck stiffness and
positive Kernig’s sign, uncontrolled shaking of the body,
and ultimately slipped into a coma. He had been admi-
nistered the JE vaccine 1 week prior to his illness. Case
3 was a previously healthy four-year-old girl. She was
admitted to hospital C on 1 July with symptoms of
fever, severe headache and altered mental status. On
admission, the patient’s temperature was 37°C, and this
rose to 40°C after hospitalization. No vomiting or diar-
rhea was noted. Severe meningeal irritation signs were
also present. She then developed abnormal muscle tone,
and finally became unconscious. She had received the JE
vaccine 14 days prior to the onset of illness. Case 4,a
five-year-old boy exhibiting normal growth, was febrile
on 7 July and was admitted to hospital C on 10 July
with fever of 40°C. The prodromal symptoms of the boy
included headache, nausea and vomiting. Irritability and
neck stiffness were also present but the patient was
alert. During a physical examination, abnormal muscle
tone (hypertonia) and abnormal limb reflexes (hyperre-
flexia) were detected. He then rapidly lost consciousness.
11 days prior to the onset of fever, he received one dose
of the JE vaccine. No allergic reaction or other remark-
able medical history was recorded in the four cases.
Table 1 illustrates the interval between illness onset and
CSF with or without serum sample collection (≤ 4 days).
Laboratory tests for Case 1 indicated a normal serum
leukocyte count (8.5 × 10
3 cells/mm
3), high levels of
neutrophilic granulocytes (74.4%) and a normal CSF
Table 1 Characteristics of the four cases in this study
Characteristics Case 1 Case 2 Case 3 Case 4
Age 9 months 4 years 4 years 5 years
Sex Female Male Female Male
Days from vaccination to onset of disease 11 7 14 11
Past medical history None None None None
Other vaccines None None None None
Days from the onset of symptoms to CSF with or without serum sample collection 4 1 4 3
CSF color Clear Clear Clear Clear
JEV IgM antibodies in CSF* Positive Positive Positive Positive
JEV IgM antibodies in serum* Positive NA Positive NA
* Serological testing was conducted by Japanese encephalitis virus-specific immunoglobulin M (IgM) antibody-capture enzyme-linked immunosorbent assay
CSF: cerebrospinal fluid
NA: not available
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3;n o r m a lr a n g e :0 - 1 0
WBCs/mm
3). Elevated protein levels (560 mg/L; normal
range: 200-400 mg/L) but normal glucose levels (3.31
mmol/L; normal range: 2.8-4.4 mmol/L) were detected
in the CSF. A Gram stain revealed no organisms. The
CSF biochemical parameters of other three cases were
not available. All CSF samples were positive for JEV-
specific IgM antibodies as analyzed by the MAC-ELISA
(Table 1). Viral isolation and PCR for JEV were both
negative for the CSF and serum samples. Testings for
other aetiologies of meningoencephalitis were not con-
ducted. Brain magnetic resonance imaging (MRI) was
not performed in these hospitals.
The therapy for all cases consisted of supportive care
and the management of complications, such as the use
of empirical intravenous antibiotics to prevent possible
bacterial infection and the injection of intracranial ten-
sion-lowering agents (e.g., mannitol). All patients were
discharged from the hospital, but their sequelae were
not followed-up by interview.
Discussion
In the present study, we report four laboratory-con-
firmed JE cases, confirmed by positive IgM levels in
their CSFs, who all received a first dose of a live attenu-
ated JE vaccine within 2 weeks prior to the onset of
symptoms. It is difficult to identify a causal link between
the disease and JE vaccination, because no etiological
evidence such as positive viral isolate or nucleotide was
found.
I tm i g h tb ef e a s i b l et oc o n s i d e rt h ee v e n t sm i g h tb e
due to JE vaccination. However, the live SA 14-14-2
attenuated vaccine is safe based on available data. A
large randomized clinical trial involving 26,239 children
demonstrated good short-term safety of the live attenu-
ated vaccine. No cases of encephalitis or meningitis
occurred in subjects who received the vaccine [4]. In a
study begun in 1985, 1026 children were vaccinated
with live-attenuated vaccine (SA14-14-2 strain), and
none of these children had temperatures greater than
37.4°C or other systemic reactions during the observa-
tion period after vaccination [5]. Until now, there have
been no other reported cases of neurological adverse
events despite the live attenuated vaccine being used in
several hundred million children over a period of 20
years [11]. During our further interview, the batch num-
bers of the vaccine administrated by the four cases were
not clearly remembered by their guardians. It made our
in-depth investigation of the vaccine safety difficult.
Furthermore, it is important to note that all cases
were detected during the peak circulation period of JEV
in a JE-endemic area with relatively high JE incidence.
In this study, 36 (43%) out of 84 children with viral
encephalitis were diagnosed with JE. This high rate of
JEV transmission suggests a high risk of natural infec-
tion. The incubation period for JE is 5-15 days [7].
Therefore, it may also suggest a reasonable likelihood of
these cases being caused by a wild-type virus. JE vacci-
nation is very unlikely to prevent a wild-type infection
acquired around the same time as vaccination was given.
A third possibility, although less likely, is a traumatic
tap when lumbar puncture was conducted with neurolo-
gical infection due to another etiology. Anti-JEV IgM
would be expected in the serum of patients vaccinated
with live attenuated JE vaccine, and indeed was detected
in two cases reported. In the case of a traumatic lumbar
puncture, the anti-JEV IgM detected in CSF may be
from blood contamination.
Conclusions
This report highlights the need for public health officers
and doctors to consider reasonable vaccination policies
during the JE season. JE vaccination should be recom-
mended outside of a well-defined JEV transmission sea-
son. If vaccination is administered during the
transmission season, a clear explanation should be pro-
vided that the vaccine is not likely to prevent illness if a
person has already been infected at the time of vaccina-
tion. In addition, continued good quality surveillance as
well as thorough investigation of any events that occur
after JE vaccination is necessary.
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